Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Gains from Investment Securities (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Gains from Investment Securities readings, the most recent being $4.5 million for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 36.72% to $4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.3 million, a N/A change, with the full-year FY2025 number at $18.3 million, changed N/A from a year prior.
  • Gains from Investment Securities hit $4.5 million in Q4 2025 for Amicus Therapeutics, down from $17.8 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $17.8 million in Q3 2025 to a low of -$16.6 million in Q2 2024.
  • Median Gains from Investment Securities over the past 5 years was $1.1 million (2022), compared with a mean of $1.9 million.
  • The widest YoY moves for Gains from Investment Securities: up 67490.48% in 2021, down 81305.88% in 2021.
  • Amicus Therapeutics' Gains from Investment Securities stood at -$4.3 million in 2021, then plummeted by 133.46% to -$10.0 million in 2022, then surged by 252.74% to $15.3 million in 2023, then crashed by 54.05% to $7.0 million in 2024, then plummeted by 36.72% to $4.5 million in 2025.
  • The last three reported values for Gains from Investment Securities were $4.5 million (Q4 2025), $17.8 million (Q3 2025), and -$2.8 million (Q2 2025) per Business Quant data.